shares jumped about 6.5 per cent in early trade on Thursday, hitting a 52-week high, as strong quarterly earnings and upbeat growth visibility boosted investor sentiment. The stock rose to a high of ₹7,200 and closed flat at ₹6,821 on the NSE, compared to the previous close of ₹6,758.50.
Navin Fluorine stock today
The company reported a 76.2 per cent y-o-y rise in standalone net profit at ₹135.03 crore for the quarter ended March 2026, up from ₹76.61 crore in the year-ago period. Revenue from operations grew 29 per cent y-o-y to ₹626.51 crore, supported by a strong performance across key segments.
On a full-year basis, profit after tax more than doubled to ₹487.67 crore in FY26 from ₹241.93 crore in the previous year. The board also recommended a final dividend of ₹8.60 per share.
Global brokerages remained divided on the stock despite the strong performance. Jefferies maintained a ‘buy’ with a target price of ₹8,385, noting that EBITDA and profit after tax beat its estimates by 19 per cent and 30 per cent, respectively, driven by strength in specialty chemicals and CDMO segments. It highlighted that multi-year contracts, capacity expansion in key products and a strong balance sheet position provide visibility for earnings growth over FY27–FY28, and expects a 24 per cent EPS CAGR over FY26–FY28.
Citi maintained sell with a target price of ₹6,500, pointing out that while EBITDA rose 80 per cent y-o-y and margins remained strong at 34.2 per cent, much of the growth outlook appears priced in after the stock’s sharp rally over the past year. It also flagged potential downside risks to refrigerant pricing amid capacity additions, which could impact future profitability.
DAM Capital retained buy with a target price of ₹7,769, highlighting broad-based strength with the sixth consecutive quarter of growth in revenue and profitability. It noted strong momentum in specialty chemicals and CDMO businesses, along with improving utilisation levels in new projects, while management remains confident of sustaining EBITDA margins around 30 per cent.
Among domestic brokerages, Elara Capital reiterated buy with a revised target price of ₹8,681, citing improved earnings visibility and a transition into a multi-year compounding phase. It expects robust growth driven by CDMO ramp-up, execution of key projects and favourable industry tailwinds, while maintaining a strong earnings growth outlook over the medium term.